問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2025-11-06

曾政森TSENG, JENG-SEN
  • Principal Investigator
  • Clinical Trial Experience (year)

  • tzeng64@gmail.com

Recruiting Trial

133Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾政森

List

222Cases

2013-04-01 - 2018-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2012-12-14 - 2018-04-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2012-10-22 - 2014-11-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-02-01 - 2023-03-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2016-01-31 - 2017-02-10

Phase I

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1)) will evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 in adult patients with solid tumors. A dose exploration cohort will look at the safety profile of Q4W dosing of MEDI4736.

  • Condition/Disease

    NSCLC

  • Test Drug

    MEDI4736 & Tremelimumab

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

2017-02-10 - 2025-12-31

Phase III

A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti PD 1 Antibody) versus Platinum Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic PD L1 + Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN2810

Participate Sites
17Sites

Recruiting13Sites

Terminated2Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張家崙
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Hematology & Oncology

2020-03-10 - 2026-05-21

Phase I

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    CLN-081

Participate Sites
7Sites

Recruiting7Sites

2022-11-30 - 2027-10-31

Phase III

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

  • Condition/Disease

    Metastatic Non Small Cell Lung Cancer

  • Test Drug

    Datopotamab deruxtecan (Dato-DXd；DS-1062a)

Participate Sites
9Sites

Recruiting9Sites

2022-03-01 - 2028-04-30

Phase III

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

  • Condition/Disease

    Metastatic Non Small Cell Lung Cancer

  • Test Drug

    datopotamab deruxtecan (Dato-DXd; INN: DS-1062a)

Participate Sites
9Sites

Recruiting9Sites

2019-05-01 - 2022-12-31

Phase II/III

A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (Erlotinib or Gefitinib), as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis

  • Test Drug

    AZD3759

Participate Sites
4Sites

Recruiting4Sites

1 19 20 21 22 23
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB